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THE AUTOMATIC SEGMENTATION OF THE HUMAN AMYGDALA  





Background: Mild cognitive impairment (MCI) is a clinical condition that is characterized 
by mild changes in cognition. The amnestic form of MCI (aMCI) primarily affects memory 
and is thought to represent a stage between healthy aging and Alzheimer’s disease (AD). 
The medial temporal lobe (MTL) and the limbic system are two areas of the brain that have 
been implicated in the amnestic form of MCI. While MCI represents a risk factor for AD, 
it does not always lead to dementias. Being a carrier of the APOE Ɛ4 allele has also shown 
to increase chances of progression from MCI to AD. 
Objective: To determine whether the subnuclei of the amygdala, along with other specific 
regions within the MTL, can differentiate between cognitively normal individuals and age-
matched subjects with aMCI. 
Methods: T1-weighted magnetic resonance imaging (MRI) data from two sources, the 
Boston University Alzheimer’s Disease Center (BU-ADC) and the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI), was compiled for cross-sectional analysis. 95 scans in 
total from 45 cognitively normal participants and 50 diagnosed with aMCI were analyzed 
and the volumes of interest were automatically generated by the developmental version of 
FreeSurfer v6.0. To evaluate how well the volumes could predict either group membership 
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(i.e. control group or MCI group) or APOE Ɛ4 status (i.e. carrier or noncarrier), the 
variables were assessed by nominal logistic regression models. 
Results: Six of the nine nuclei of the amygdala had significantly reduced volumes in the 
aMCI group compared to controls. The whole amygdala and the perirhinal cortex also 
demonstrated reduced volumes in the aMCI group compared to the control group. The 
whole amygdala was a good predictor of group membership (R2 = 0.1386, whole model 
test chi square = 18.21558, p = 0.0004), but none of the subnuclei were good predictors 
individually. A model containing the 9 nuclei, the entorhinal cortex, and the perirhinal 
cortex provided a good fit for predicting APOE Ɛ4 status fit (R2 = 0.3000, whole model test 
chi square = 36.29563, p = 0.0002) and the best predictor was the corticoamygdaloid 
transition area of the amygdala.  
Conclusions: The results of our study confirm previous findings of reduced whole 
amygdala volume and add to the limited literature of reduced perirhinal cortex and 
amygdaloid nuclei volumes in MCI compared to healthy controls. To the best of our 
knowledge, this was the first time the automatic segmentation atlas was used to analyze 
the volumes of nine subnuclei of the amygdala in a population of aMCI. Our model testing 
the volume of the whole amygdala accurately predicted aMCI subjects with 58% accuracy 
and controls with 70% accuracy; the accuracy rose to 69% when the entorhinal cortex and 
the perirhinal cortex were added to the model to predict aMCI subjects from controls. 
Additionally, the model for predicting APOE Ɛ4 status identified noncarriers of the allele 
at 85% accuracy. Future studies should consider increasing the sample size to better assess 
small ROIs and assess for differences in the separate hemispheres. 
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Background on Dementia 
 Dementia is a broad term for various diseases and conditions that cause cognitive 
impairment. Affected functions include memory, language, visual perception, problem 
solving, and control of emotions. It is important to note that though dementia is more 
common as people age, it is not considered a normal part of aging. Up to half of all people 
aged 85 or older may experience some form of dementia, but the other half may live into 
their 90s and beyond without any significant signs of loss in cognitive functioning 
(National Institute on Aging, 2020).  
 Many dementias are progressive and caused by abnormal changes in the brain that 
can be detected by brain scans such as magnetic resonance imaging (MRI) (Alzheimer’s 
Association, 2020). The first steps in diagnosing dementia generally involve collecting 
medical history and performing neuropsychological tests when a patient or someone close 
to them has a concern (National Institute on Aging, 2020). It is often difficult to determine 
the cause or the exact type of dementia with this information and doctors and patients may 
opt to also collect blood or cerebrospinal fluid (CSF) as well as imaging data from MRI 
and Positron Emission Tomography (PET) (National Institute on Aging, 2020; 
Alzheimer’s Association, 2020).  
Alzheimer’s disease (AD) is the most common type of dementia, accounting for 60 
to 80 percent of dementia related cases. Changes in the brain begin long before any clinical 
signs are recognized; the most common early symptom of AD is difficulty remembering 
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newly learned information, which is characterized by a rapid rate of forgetting 
(Alzheimer’s Association, 2020). Memory loss is mild in early stages, but as the disease 
advances to later stages the impairments grow in severity and symptoms include 
disorientation, mood and behavior changes, and difficulty speaking and walking.    
The greatest risk factor for AD is aging. Most individuals affected by this 
progressive disease are age 65 or older, and after the age of 65 the risk of AD doubles every 
five years (Alzheimer’s Association, 2020). Family history is also a risk factor; those with 
a parent or sibling affected by AD are more likely to develop the disease themselves. One 
of the most important and widely studied genetic factors for AD is the apolipoprotein E 
(APOE) Ɛ4 allele (Caselli et al., 2007; Liu et al., 2015; Tang et al., 2015). There are three 
forms of APOE in humans: Ɛ2, Ɛ3, and Ɛ4. The most common allele is Ɛ3 and is found in 
more than half of the general population. Research has shown that memory declines more 
rapidly with age in carriers of the Ɛ4 allele than in noncarriers (Caselli et al., 2004) and 
being a carrier of APOE Ɛ4 reduces the median age of AD onset from age 84 years in 
noncarriers to 68 in Ɛ4 homozygotes (review in Caselli et al., 2007).  
There is currently no cure for AD, but treatments exist to slow the progression and 
improve quality of life (Alzheimer’s Association, 2020). Efforts for early detection, 
delaying onset, and overall prevention from development are hastily being studied 
worldwide. 
 
Epidemiology of MCI 
 Mild cognitive impairment (MCI) is a clinical diagnosis that describes changes in 
cognition and is thought to be a step between healthy aging and AD (Petersen et al., 2001). 
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MCI can affect a number of functions; amnestic MCI (aMCI) primarily affects memory, 
whereas nonamnestic (single or multi-domain) MCI can affect decision making, judgment, 
or visual perception. These declines are greater than normal for alone and can be noticed 
by the person affected and people close to them; however, these cognitive declines are not 
significant enough to affect their daily function. Approximately 15 to 20 percent of people 
age 65 or older experience MCI (Alzheimer’s Association, 2020).  
 MCI has been widely studied as a precursor to AD and other dementias, but 
it does not always lead to dementia. In some individuals, the symptoms remain stable or 
even revert back to normal cognition. When cognitive impairment begins to affect daily 
life, clinicians are likely to diagnose the progression as AD (Aisen et al., 2017). aMCI has 
a high risk of progression to AD (Gauthier et al., 2006), and being a carrier of the APOE 
Ɛ4 allele has shown to increase chances of progression from MCI to AD (Petersen et al., 
1995). The Food and Drug Administration (FDA) has not approved any medications to 
treat MCI and the drugs that have been approved to treat symptoms of AD have not shown 
to prevent or delay the progression of MCI or AD (Alzheimer’s Association, 2020). 
 
Neuroanatomic Characteristics 
The medial temporal lobe (MTL) has been extensively studied in relation to MCI 
and AD due to its role in memory. The MTL is described as a system of anatomically 
related structures including the hippocampus, entorhinal cortex, and perirhinal cortex 
(Squire et al., 2004). Together these structures are primarily concerned with memory and 
the connection has been well documented since the famous resection in patient H.M. 
(Scoville & Milner 1957). H.M. suffered from epilepsy and underwent a surgery to remove 
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sections of his MTL in hopes of ameliorating his symptoms. The side effects of the surgery 
included his inability to form new declarative memories, though he was able to retain his 
memories prior to the procedure. It is therefore not surprising that the MTL has been 
connected to memory loss in amnestic patients and widely studied in patients with MCI 
and AD.  
A meta-analysis on the neuroanatomic changes in cognitive decline in MCI points 
to the MTL as having gray matter atrophy, and a sub-analysis in aMCI revealed a similar 
pattern (Nickl-Jockschat et al., 2012). The main findings highlighted changes in the 
hippocampus, thalamus, and amygdala – collectively parts of the limbic system. A more 
recent volumetric study found smaller volumes bilaterally in the thalami and hippocampi 
of AD patients compared to controls as well as aMCI patients to controls. Additionally, 
they found a difference in bilateral amygdalae volumes of AD patients compared to 
controls, but did not reach significance when comparing aMCI to controls (Zidan et al., 
2019).  
The entorhinal and perirhinal cortices, adjacent to the hippocampus, have also been 
studied in relation to MCI (review in Delhaye et al., 2019). The entorhinal cortex, known 
as the gateway to the hippocampus, has been more thoroughly studied and thought to be 
affected early by AD neuropathology and specifically linked to associative memory deficits 
in MCI patients (Atienza et al., 2011). Similarly, the volume of the perirhinal cortex has 




The hippocampus and the amygdala, though often studied as separate entities, are 
heterogeneous structures that can be divided into several subfields (de Flores et al., 2015 
for a hippocampus review; Saygin & Kliemann et al., for an amygdala review).  
The hippocampal formation contains 24 subfields (12 in each hemisphere), which 
have been extensively studied in healthy aging and AD (de Flores et al., 2015; Iglesias et 
al., 2015; 2016). 18 of the 24 subfields have shown to be volumetrically smaller in patients 
with MCI compared to controls (DeVivo et al., 2019). Devivo et al. also noted decreased 
volumes in the left and right entorhinal cortices in patients with MCI compared to controls.  
Also known as the amygdaloid body or the amygdaloid nuclear complex (V. Di 
Marino et al., 2016), the amygdala contains several nuclei that can be differentiated from 
one another by cytoarchitecture (Brockhaus 1938, 1940) and as of more recently, MRI data 
(Saygin & Kliemann et al., 2017). There is debate over exactly how many distinct nuclei 
there are in the human amygdala, but a recently developed FreeSurfer atlas for amygdala 
nuclei can reliably distinguish up to nine in each hemisphere and are listed in Table 1 
(Saygin & Kliemann et al., 2017). Utilizing the Alzheimer’s Disease Neuroimaging 
Initiative (ADNI) database, they found that volumetric data of the amygdala nuclei can 
discriminate between AD patients and controls with 84% accuracy (Saygin & Kliemann et 







Table 1. Overview of Anatomical Boundaries of 9 Unilateral Amygdala Nuclei. 




AAA The AAA represents the anterior end of the amygdala. 
AAA borders CAT anteriorly and laterally and has a 
concave crescent shape. In its most posterior and 
lateral position, AAA detaches from the rest of the 
amygdala and extends until striatal tissue becomes 
visible. AAA appears as a bright band anteriorly, 





CAT The CAT represents the medial border of the 
amygdala. Laterally CAT borders AAA, AB, Ba, PL 
and Ce along its anterior-posterior extent. The 
posterior portion of CAT is inferior to the medial 
nucleus. CAT’s ventral border merges into the 
hippocampal-amygdala transition area (HATA) 
posteriorly. Occasionally, the CAT showed poor 
contrast at its anterior borders. 
Lateral 
Nucleus 
La In the anterior portion of the amygdala, the La is 
typically the first nucleus to appear. Scrolling 
anterior-posterior in the coronal plane, the La 
transforms from a circular/oval shape into a wedge or 
triangular shape. The La’s medial border remains next 
to the Ba along the entire amygdala. The anterior La 
borders AAA, rostrally and laterally. The La 
continues laterally and dorsally until the posterior end 
of the amygdala. La is by far the largest nucleus of the 
amygdala, and reveals excellent contrast in all cases. 
Basal Nucleus Ba The anterior appearance of the Ba follows its lateral 
neighboring nuclei (La) and borders La throughout 
the amygdala. When viewed in coronal plane, Ba is 
circular anteriorly, then progresses into an L-shape 
midway, and ends circular. 
Paralaminar 
Nucleus 
PL The PL is a small, light band that is inferior to Ba, 
lateral to CAT, and ventro-medial to part of the La. 
PL borders Ba and La and remains until the last few 
slices while transitioning more medially towards the 
CAT and AB. 
Accessory 
Basal 
AB From anterior to posterior coronal slices, the AB 
emerges medially from/within the Ba in a circle that 
transforms into an oval shape. Dorsally, it forms an 
obtuse angle with Ba. Medially, the AB borders CAT, 
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Me The Me emerges near the optical tract and can be 
visible along most of the anterior-posterior extent of 
the amygdala. The Me covers most of the lateral-
dorsal boundary of CAT. This nucleus is the most 
variable in shape, being either elongated and slim or 
more circular in coronal view. The axial view is useful 
in verifying the borders of this nucleus. 
Central 
Nucleus 
Ce The Ce appears circular and dorsal to AB and is 
between CAT medially and Ba laterally. For about 
half the cases, the Ce remains a circular shape, and for 
the other half of the cases, it becomes progressively 
more oval. The Ce appears brighter than its 
surrounding tissue. The axial view is useful in 
verifying the borders of this nucleus. 
Cortical 
Nucleus 
Co The Co emerges as a small circular nucleus, dorsally 
to CAT. The AB borders Co laterally. Overall, the Co 
is the smallest nucleus in size and contains the fewest 
number of slices labeled in the atlas. 
Adapted from ‘High-resolution magnetic resonance imaging reveals nuclei of the human amygdala: manual 
segmentation to automatic atlas’ (Saygin & Kliemann et al., 2017). 
 
Another study utilizing the ADNI database specifically examined the effects of 
APOE Ɛ4 on the volume of the hippocampus and amygdala in MCI and AD (Tang et al., 
2015). They found volumetric reductions in APOE Ɛ4 carriers compared to non-carriers in 
the right hippocampus of the AD group and found differences in bilateral hippocampi and 
right amygdala in MCI carriers of APOE Ɛ4 compared to non-carriers. Using the 
segmentation module of FreeSurfer version 4.3.0, this study looked at four (unilateral) 
subregions of the amygdala: the basolateral, basomedial, centromedial, and lateral nuclei. 
Out of the four, the basolateral, centromedial, and lateral nuclei showed signs of significant 
atrophy (Tang et al., 2015). The newer version of FreeSurfer can further divide the 
unilateral amygdala into five more nuclei (Saygin & Kliemann et al., 2017). 
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 The roles and functions of each of the nine nuclei remain unclear. The amgydala as 
a whole has been associated with emotion, memory, associative learning, and fear 
conditioning (review in Gallagher & Chiba, 1996).  Limited studies have made inferences 
on the functions of the individual nuclei. It is thought that the basolateral nucleus (a 
combination of the basal, lateral, and accessory basal nuclei) is involved with taste and 
odor potentiation learning and appetitive learning (review in Gallagher & Chiba, 1996; 
Baxter & Murray, 2002).  Additionally, the central nucleus along with the basolateral have 
been associated with aversive conditioning (review in Gallagher & Chiba, 1996; Baxter & 
Murray, 2002).   
The objective of our study is to utilize the newest version of FreeSurfer (v6.0) and 
the automatic segmentation atlas to measure the volumes of the nine unilateral nuclei of 
the amygdala in patients with MCI and control subjects. Saygin and Kliemann et al. found 
that the automatic segmentation atlas discriminated between a population of AD subjects 
and controls with 84% accuracy (Saygin & Kliemann et al., 2017). AD subjects are 
expected to have more volumetric declines than MCI subjects, but nevertheless we expect 
to find lower whole amygdala volumes in our MCI population and explore the nine 
subnuclei to identify variables that can classify control subjects and MCI subjects using 
logistic regression. Further, because we expect our discrimination percent accuracy to be 
lower in MCI than AD, we are including additional regions of interest from the medial 






Subjects and Materials 
 Our study sourced subjects from two databases: the Health Outreach Program for 
the Elderly (HOPE) and the Alzheimer’s Disease Neuroimaging Initiative (ADNI). HOPE 
is part of Boston University’s Alzheimer’s Disease Center (BU-ADC), is funded by the 
National Institute on Aging (NIA), and contributes data to the National Alzheimer’s 
Coordinating Center (NACC) (more information can be found at 
https://www.bu.edu/alzresearch/research/recruiting-studies/hope/). HOPE is a community-
based study focused on recruiting English speaking participants with and without memory 
concerns who undergo annual neurological and neuropsychological evaluations; 
recruitment criteria previously described elsewhere (Galetta et al., 2017). 
 The ADNI database is a multicenter study that began in 2004 under the leadership 
of Dr. Michael W. Weiner (more information can be found at http://adni.loni.usc.edu/). 
This longitudinal study recruited participants from 63 sites across the United States and 
Canada to identify AD biomarkers and track progression; the study design has been 
previously described in detail (Mueller et al., 2005). 
 42 scans from the HOPE database were included in analysis. Subjects’ diagnoses 
were agreed upon at consensus conferences following presentations of their medical 
history, clinical interview, neuropsychological test scores, and MRI scans. 19 of the HOPE 
scans utilized in this study were from subjects determined to be cognitively normal with a 
Clinical Dementia Rating global score of 0.0 (Morris, 1993). The remaining 23 scans were 
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from subjects diagnosed with amnestic MCI. 53 scans from the ADNI database included 
26 cognitively normal subjects and 27 were diagnosed with amnestic MCI.  
In total, 95 scans were analyzed in this study (42 HOPE and 53 ADNI; 45 control 
and 50 aMCI; 52 females and 41 males). Both databases collected the following 
demographic data for all participants: age, education, and APOE Ɛ4 status. Additionally, 
neuropsychological test scores were available from the Mini-Mental State Exam (MMSE), 
Geriatric Depression Scale (GDS), Logical Memory Recall (modified from the Wechsler 
D. Wechsler Memory Scale-Revised (WMS-R) San Antonio, Texas: Psychological 
Corporation; 1987), and Part B of the Trailmaking Test. The neuropsychological test scores 
were previously analyzed in Devivo et al. (Devivo et al., 2019). 
Image Processing 
 All 95 T1-weighted scans were acquired on 3T Philips scanners and our study 
utilized the 3D magnetization-prepared rapid acquisition of gradient echo (MPRAGE) 
sequence scans. The MPRAGE sequence being used in the ADNI study was developed on 
a Philips scanner at Boston University and then distributed to the other Philips scanners 
being used in the ADNI study (Clifford et al., 2008). 
The HOPE scans were acquired using a 32-channel headcoil and sense factor of 2 
with the following imaging parameters: TR = 6.7 ms, TE = 3.1 ms, flip angle = 9°, 
reconstructed and acquisition voxel size = 0.98 x 0.98 x 1.2 mm, FOV = 250 mm x 250 
mm x 180 mm, 150 sagittal slices. The ADNI scans utilized for this study were acquired 
with an 8-channel headcoil and a sense factor of 1.8 with the following imaging parameters: 
TR = 6.8 ms, TE= 3.1 ms, flip angle = 9°, reconstructed voxel size = 1.05 mm x 1.05 mm 
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x 1.20 mm, acquisition voxel size = 1.11mm x 1.11mm x 1.20mm, FOV = 270mm x 252 
mm x 240 mm, 170 sagittal slices.  
 The MRI data from both databases were automatically segmented with the 
developmental version of Freesurfer v6.0 (http://surfer.nmr.mgh.harvard.edu; for 
additional details see Desikan et al., 2006; Iglesias et al., 2015). The dataset had been 
previously processed and segmented with the automatic atlas for hippocampal subfields, 
and a subset was visually inspected for errors and edited as needed; upon finding no 
significant errors, the cortical surfaces were not edited (Devivo et al., 2019). The MRI data 
was further processed for the purpose of this paper by the developmental version of 
Freesurfer v6.0, with an evolved and improved atlas that can automatically segment the 
nuclei of the amygdala into a greater number than previous versions have allowed (Iglesias 
et al., 2015; Saygin & Kliemann et al., 2017). 
Statistical Analysis  
 To assess whether the 95 participants were matched in demographics (age and 
education level), we performed independent t-tests between the control and MCI groups. 
Additionally, independent t-tests were used to assess differences between the two groups 
(i.e. MCI and control) and MRI measure outcomes. Chi square tests were used to determine 
differences between the groups in terms of APOE Ɛ4 status and sex (male/female). A 
conservative p-value of 0.01 was used to assess the significance of these tests. 
 Freesurfer v6.0 generated volumes for estimated total intracranial volume (eTIV), 
ex vivo (cytoarchitecturally-defined) entorhinal cortex (Brodmann’s Area 28), ex vivo 
perirhinal cortex (Brodmann’s Area 35) (Augustinack et al., 2013), and the amygdala. The 
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amygdala volumes were then further subdivided into 9 nuclei (see Table 1). In this study 
we summed the volumes of separate hemispheres to solely report on the bilateral regions 
of interest. 
 Nominal logistic regression models were created to determine the efficacy of the 
volumetric MRI data in identifying group membership (i.e. control or MCI group). This 
study utilized volumes of the whole amygdala, whole entorhinal cortex, whole perirhinal 
cortex, and whole hippocampal formation. The same models were run to assess whether 
the volumes could predict APOE Ɛ4 status. 
 Devivo et al. performed an ANCOVA to determine whether factors such as eTIV, 
age, sex, education, APOE Ɛ4 status, or study (i.e. HOPE and ADNI) had a significant 
effect on volumetric MRI variables (Devivo et al., 2019). They found that age and eTIV 
had a significant effect on volumes, while the other factors had no significant impact. To 

















 Table 2 shows the demographic data for the 95 participants (42 HOPE and 53 
ADNI; 45 controls and 50 aMCI). There were no significant differences between groups 
in terms of age, years of education, sex, or APOE Ɛ4 status (p’s > 0.01). 
 
Table 2. Demographic Data for Control and MCI Groups. 
 
(n=95) 
Means for Control 
Group (  Standard 
Deviation) 
Means for MCI 




























35.6% of Controls 
identified as male 
 
 
48% of MCI 











38.6% of Controls 
are carriers of at 
least 1 Ɛ4 allele 
 
 
32.65% of MCI are 










 Figure 1 illustrates the comparisons of volumes of the whole regions of interest. 
Significant differences (p’s < 0.01) were found when comparing the whole amygdala and 
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the whole perirhinal cortex, but not the entorhinal cortex. The MCI group had significantly 
lower volumes in whole amygdala and perirhinal cortex compared to the control subjects. 
 Figure 2 shows the volumes on the bilateral nuclei of the amygdala in both subject 
groups. The lateral nucleus, basal nucleus, accessory basal nucleus, anterior amygdaloid 
area, cortical nucleus, and corticoamygdaloid transition area showed significant 
differences (p’s < 0.01) with lower volumes in the MCI group compared to the controls. 
Structures such as the central nucleus and paralaminar nucleus were not significant even 
though they had a value of p < 0.05 value because we chose to use the most conservative 
value of p = 0.01 to counteract our multiple comparisons. The medial nucleus was not 
significant under either p < 0.01 or p < 0.05 (see Table 3 for all p values).    
Table 3. Mean Total Volumes, p Values, and Standard Deviations. 
Total volumes and standard deviations (StDev) are listed for both control group and MCI group. Significant differences 
(p < 0.01) between groups are denoted with a (*).








3386.4 2673.16 3082.046 97.13 309.56 1195.94 788.24 92.84 445.51 34.82 75.61 42.41 
p-value 0.0041* 0.136 0.00195* 0.00187* 0.005* 0.002* 0.0028* 0.0194 0.00186* 0.0886 0.0188 0.0044* 
Control 
StDev 538.34 603.50 380.48 14.26 46.88 126.15 101.94 10.34 74.96 8.90 18.68 8.15 
MCI 




Figure 1. Mean Total Volumes of Bilateral Perirhinal and Entorhinal Cortices and 
Amygdala. 
 
The mean total bilateral volumes (sum of left and right hemisphere) of the perirhinal and 
entorhinal cortices and amygdala were measured in groups of control and MCI subjects. 
The perirhinal cortex and the amygdala show significant differences (p < 0.01) between 
groups and are denoted with a (*), demonstrating a volume reduction in MCI subjects in 
comparison to the control group. Error bars represent standard error of the means. MCI = 



































Mean Total Volumes of Bilateral Regions of Interest








The mean total bilateral volumes (sum of left and right hemisphere) of the 9 nuclei of the 
amygdala were measured in groups of control and MCI subjects. 6 of the 9 nuclei show 
significant differences (p < 0.01) between groups and are denoted with a (*), 
demonstrating a volume reduction in MCI subjects in comparison to the control group. 
Error bars represent standard error of the means. MCI = Mild Cognitive Impairment 
 
 
 We used nominal logistic regression models to determine how well the regions of 
interest could predict group membership. The model for whole amygdala was significant 

































Mean Total Volumes of Bilateral Amygdala Nuclei 









of the amygdala produced significant models nor did the entorhinal cortex or perirhinal 
cortex (see Table 4 for values). 
Table 4. Predictors of Group Membership. 
Region FDR P Value 
Whole Amygdala 0.00008* 
Lateral Nucleus 0.30029 
Perirhinal Cortex 0.35141 
Central Nucleus 0.60704 
Accessory Basal Nucleus 0.74553 
Paralaminar Nucleus 0.74553 
Medial Nucleus 0.79943 
Cortical Nucleus 0.79943 




Anterior Amygdaloid Area 0.98031 
Basal Nucleus 0.98031 
 
Significant differences (p < 0.01) are denoted with a (*). Note: the whole amygdala was 
run in a separate model correcting for age and eTIV and the nuclei, entorhinal cortex, and 
perirhinal cortex were collectively run in a model also correcting for age and eTIV. 
 
 A nominal logistic regression model was also run to determine how well the 
volumes of our regions of interest were at predicting APOE Ɛ4 status. Our model included 
the nine nuclei of the amygdala as well as the entorhinal cortex and the perirhinal cortex. 
The best predictor out of the group and the only region to reach significance (p < 0.01) was 
the corticoamygdaloid transition area (FDR p value = 0.00033). The cortical nucleus, 
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lateral nucleus, and medial nucleus saw a trend towards significance (see Table 5 for p 
values). The overall model provided a good fit (R2 = 0.3000, whole model test chi square 
= 36.29563, p = 0.0002) and correctly identified 51 out of the 60 noncarriers of the APOE 
Ɛ4 allele. However, the model was not as good at predicting those who were carriers of the 
APOE Ɛ4 allele, only correctly predicting 19 of the 33.  
Table 5. Predictors of APOE Ɛ4 Status (Carrier vs. Noncarrier). 




Cortical Nucleus 0.01326 
Lateral Nucleus 0.02375 
Medial Nucleus 0.02786 
Basal Nucleus 0.20040 
Perirhinal Cortex 0.29544 
Accessory Basal Nucleus 0.29544 
Central Nucleus 0.74288 
Anterior Amygdaloid Area 0.74288 
Entorhinal Cortex 0.79263 
Paralaminar Nucleus 0.95466 
 







 Our study utilized a dataset that had been previously analyzed by another group 
who reported on a different set of regions of interest with a focus on the hippocampal 
subfields (Devivo et al., 2019). One participant from the original dataset was excluded in 
our study and we reanalyzed the demographic data.  The MCI and control groups were well 
matched for age, sex, years of education, and APOE Ɛ4 status. Devivo and colleagues 
reported expected differences between groups on four neuropsychological test scores: 
Logical Memory Immediate Recall, Logical Memory Delayed Recall, MMSE, and Part B 
of the Trailmaking Test. The neuropsychological test scores were not expected to change 
and were therefore not analyzed again for the purpose of this study.  
MRI 
 In this study, smaller volumes were noted in the whole amygdala, six of the nine 
nuclei of the amygdala, and the perirhinal cortex of the MCI group compared to the control 
group. No significant differences were noted in the entorhinal cortex of the MCI group; 
previous research has been consistent with reporting reduced entorhinal cortex volumes in 
AD, but has been inconsistent when reporting volumes in MCI groups. The findings for 
the whole amygdala are consistent with other reports in the literature (Lupton et al., 2017; 
Tang et al., 2015; Zanchi et al., 2017). Similarly, the findings for the perirhinal cortex are 
consistent with other reports in the literature (review in Delhaye et al., 2019). To the best 
of our knowledge at this time, no other literature has reported on the nine nuclei of the 




 The amygdala is important for the regulation of internal emotional states and 
cognitive evaluation of emotional content (review in Gallagher & Chiba, 1996). As part of 
the limbic system, the amygdala plays a critical role along with the hippocampal region in 
emotional learning and memory (McDonald & Mott, 2017). The hippocampus along with 
the entorhinal cortex and perirhinal cortex are well interconnected with the amygdala 
(review in McDonald & Mott, 2017).  
Second to the MTL, the volume of the amygdala has been well established to be 
affected in AD and MCI subjects (Lupton et al., 2016; Nickl-Jockschat et al., 2012; Tang 
et al., 2015; Zidan et al., 2019). We were therefore not surprised to have replicated smaller 
whole amygdala volumes in our aMCI population compared to controls. 
Nuclei of Amygdala 
 The nuclei of the amygdala are cytoarchitecturally unique, but there is no clear 
consensus about the number of nuclei found within the amygdala (review in V. Di Marino 
et al., 2016). While most report that there are over a dozen nuclei found in all mammals 
(review in McDonald and Mott, 2017), the automatic atlas released through FreeSurfer 
allows for the automatic segmentation of nine nuclei per hemisphere (Saygin & Kliemann, 
2017). Saygin and colleagues tested out the automatic atlas on a population of AD subjects 
and found that the atlas was able to use the individual volumetric data of the amygdala 
nuclei to discriminate between AD participants and age-matched controls with 84% 
accuracy.   
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 We set out to test this same atlas on aMCI subjects. Due to the progressive nature 
of AD, we were not expecting to see the same level of deterioration in our aMCI group. 
Our independent t-tests showed significant volume reductions in six of the nine nuclei 
defined by the atlas. The lateral nucleus, basal nucleus, accessory basal nucleus, cortical 
nucleus, anterior amygdaloid area, and corticoamygdaloid transition reached significance 
under the conservative p < 0.01, while the central nucleus and paralaminar nucleus would 
have reached significance under the less conservative p < 0.05. The medial nucleus was 
the only nucleus to not reach significance under either value; it is the smallest nuclei by 
volume compared to the others and might have reached significance in a larger sample.  
 Limited research has been conducted on the nuclei of the amygdala, and previous 
research has grouped the nuclei into larger subregions. Tang and colleagues reported 
significant atrophy in APOE Ɛ4 carriers compared to noncarriers in MCI and AD groups 
in parts of the basolateral, centromedial, and lateral nucleus subregions (Tang et al., 2015). 
The lateral nucleus and the basal nucleus are the largest of the nine nuclei, whereas the 
central nucleus and medial nucleus are two of the smallest (see Figure 2 for graphic 
representation). It is difficult to compare our volumetric results to theirs due to their method 
of grouping the nuclei into four sections compared to our nine nuclei, but we ran a nominal 
logistic regression model to see if the nine nuclei were good predictors of APOE Ɛ4 status. 
Perirhinal Cortex 
 Research consistently shows that the medial temporal lobe, consisting of the 
hippocampus, entorhinal cortex, perirhinal cortex, and parahippocampal cortices, is one of 
the first areas affected by the pathology of AD. The hippocampus has been most 
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extensively studied due to its role in memory, which is characteristically affected in AD 
patients. The perirhinal cortex has been shown to be critical for associative memory and 
unitization (review in Delhaye et al., 2019). 
 Delhaye and colleagues reported that associative memory performance in MCI is 
related to the volume of the perirhinal cortex; subjects with MCI who had poorer memory 
performance for unitized associations also had greater atrophy to their perirhinal cortex 
(Delhaye et al., 2019). Overall, their MCI group did not show a significant reduction in 
perirhinal cortex volume. They attributed these results to their sample’s heterogeneous 
composition. Our study sample consisted of a homogenous amnestic MCI population and 
we found a significant volume reduction in the whole perirhinal cortex of our aMCI group 
compared to controls.  Few studies have reported on the volumetric differences between 
aMCI and non-amnestic single or multi-domain MCI, but it is interesting to note that both 
AD groups and our aMCI group have shown significantly reduced perirhinal volumes 
compared to control groups. 
Entorhinal Cortex 
 The entorhinal cortex has been demonstrated to be one of the first brain regions to 
be affected by AD and has shown to have significantly reduced cortical thickness in aMCI 
subjects compared to controls (Csukly et al., 2016). Though several studies have found 
smaller entorhinal cortex volumes in AD subjects compared to controls, the findings are 
not as consistent when comparing MCI to controls (review in Devivo et al., 2019). Csukly 
and colleagues reported significantly reduced cortical thickness in their aMCI group 
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compared to the control group, but did not find a significant difference in the entorhinal 
cortex volumes of aMCI compared to controls (Csukly et al., 2016). 
 Another difference to note between entorhinal cortex measurements is the two 
different labels that exist within FreeSurfer. Devivo and colleagues used the label included 
in the automatic parcellation atlas and reported a reduction in the right entorhinal cortex 
volume. In this study, we used the cytoarchitecturally-defined entorhinal cortex label and 
did not find a significant whole volume reduction. Research would benefit from more 
longitudinal data on both entorhinal cortex labels to pinpoint the stage in which the 
progression of MCI affects the integrity of the entorhinal cortex. This region is said to work 
with the hippocampus to encode episodic time with spatial inputs when storing memories, 
a function that is affected with the progression of AD (Tsao et al., 2018). It is therefore not 
surprising that the entorhinal cortex has been consistently reported to have smaller volumes 
in AD groups, but the deterioration is not as evident in MCI research. 
Nominal Logistic Model for Group Membership 
 We were interested to know if any of the nuclei of the amygdala were good 
predictors of group membership (i.e. aMCI or controls). Unsurprisingly, our model testing 
the volume of the whole amygdala was significant; it accurately predicted aMCI subjects 
with 58% accuracy and controls with 70% accuracy. When we ran the same model with 
the nuclei, none of them individually reached significance for predicting group 
membership. We added the volumes of the entorhinal cortex and perirhinal cortex to see if 
that would boost the overall significance and found that though none of the individual 
regions reached significance, the lateral nucleus and the perirhinal cortex came closest. The 
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lateral nucleus is the largest in volumetric size compared to the rest of the nuclei and with 
a larger sample size might have reached significance.  
 The overall model including the nuclei, the entorhinal cortex, and the perirhinal 
cortex was just below significance (p = 0.0213), but it performed better at predicting aMCI 
subjects at 69% accuracy compared to the whole amygdala model at 58% accuracy. We 
attribute the increase in accuracy to the perirhinal cortex and it would be interesting to see 
additional research on a larger sample size comparing the accuracy of the perirhinal cortex 
volume at predicting group membership in a sample of aMCI and AD to control subjects. 
Nominal Logistic Model for APOE Status 
While none of the nuclei were good predictors of group membership, we were 
interested to see if any would be good predictors of APOE status (i.e. Ɛ4 allele carriers vs 
noncarriers). To our surprise, not only was the model significant (p = 0.0002) when 
including the volumes of the nine nuclei, the entorhinal cortex, and the perirhinal cortex, 
but one of the individual nuclei reached significance. Under our conservative p < 0.01 
value, the corticoamygdaloid transition area reached significance and under the less 
conservative p < 0.05, the cortical, lateral, and medial nuclei would have reached 
significance. 
 Surprisingly, when we ran the model without the entorhinal cortex and perirhinal 
cortex, only including the 9 nuclei, the model achieved a higher p value of 0.0001 and the 
corticoamygdaloid transition reached a higher significance as well (p = 0.00009). In terms 
of the accuracy of predicting APOE status, both models were equally good at predicting 
the noncarriers of the APOE Ɛ4 allele at 85% accuracy. Neither model performed well 
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when predicting the carriers, but the model including the entorhinal cortex and the 
perirhinal cortex performed slightly better at 42% accuracy (compared to the one without 
the cortices at 38% accuracy). It would be interesting to see in additional research if there 
is a greater difference in predicting noncarriers and homozygous versus heterozygous 
carriers. 
Limitations 
 We are excited by our findings and realize that by overcoming some of our 
limitations, we will be able to expand on current research. Though our sample size was 
sufficient for our intended goals, a larger sample size might help us better understand some 
of the smaller regions of interest. Devivo and colleagues previously reported smaller 
volumes in 15 of the 24 uncorrected hippocampal subfields in the MCI population of this 
dataset. It was important to us that we keep the dataset the same and take a closer look at 
the nearby amygdala, specifically at the nine nuclei that had never before been studied with 
the automatic atlas in an aMCI population. It is important to note the limitation of 
nonconsenus of the nuclei among the research community, specifically the number or 
nuclei and their borders. Additionally, we know little about the functions of each nuclei 
and it is therefore difficult to infer loss of specific functions with decreases in volumes. 
 Our study would benefit from looking at the individual hemispheres, as differences 
have been noted in left and right amygdala volumes in our clinical population. 
Additionally, it would be interesting to test out the power of a model including the 
hippocampal subfields, the nuclei of the amygdala, and the neighboring regions of interest 
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within the MTL as well as the thalamus. These regions are all extensively and complexly 
interconnected and have been shown to be affected in both MCI and AD. 
Conclusion 
 The results of our study confirm previous findings of reduced whole amygdala 
volume and add to the limited literature of reduced perirhinal cortex and amygdaloid nuclei 
volumes in MCI compared to healthy controls. Though the hippocampus and the rest of 
the medial temporal lobe receive the most attention when studying memory related 
disorders, our findings provide evidence of the importance of the amygdala and the nuclei. 
Our ultimate goal is to identify biomarkers for early prediction and diagnosis of AD and 
we would benefit from including other factors in our analyses. It would be interesting to 
compare these findings to a population of aMCI, non-amnestic MCI, and AD and include 
PET and CSF measures. Further, we hope our findings will help pave the way for new 
research to study the specific functions of each nuclei in the amygdala. It would be 
interesting to see if the nuclei most affected by aMCI have more connections to the MTL 





Aisen, P. S., Cummings, J., Jack, C. R., Jr, Morris, J. C., Sperling, R., Frölich, L., Jones, 
R. W., Dowsett, S. A., Matthews, B. R., Raskin, J., Scheltens, P., & Dubois, B. (2017).
On the path to 2025: understanding the Alzheimer's disease continuum. Alzheimer's
research & therapy, 9(1), 60. https://doi.org/10.1186/s13195-017-0283-5
Alzheimer’s Association (2020). Alzheimer’s & Dementia. Retrieved from 
https://www.alz.org/alzheimers-dementia/what-is-alzheimers/causes-and-risk-factors 
Atienza M, Atalaia-Silva KC, Gonzalez-Escamilla G, Gil-Neciga E, Suarez-Gonzalez A, 
Cantero JL. (2011). Associative memory deficits in mild cognitive impairment: the role 
of hippocampal formation.  Neuroimage. 2011; 57 (4): 1331–1342. 
doi:10.1016/j.neuroimage.2011.05.047 
Augustinack JC et al. (2013) Predicting the location of human perirhinal cortex, 
Brodmann's area 35, from MRI, Neuroimage 2013 Jan 1;64:32-42. 
Baxter, M., Murray, E. (2002) The amygdala and reward. Nature Reviews. 
Neuroscience 3, 563–573 (2002). https://doi.org/10.1038/nrn875 
Brockhaus H (1938) Zur normalen und pathologischen Anatomie des Mandelkerngebietes. 
Journal of Psychology and Neurology 49:1–136 
Brockhaus H (1940) Die Cyto- und Myeloarchitektonik des Cortex claustralis und des 
Claustrum beim Menschen. Journal of Psychiatry and Neurology 49:249–348 
Caselli RJ, Reiman EM, Osborne D, et al. (2004). Longitudinal changes in cognition and 
behavior in asymptomatic carriers of the APOE e4 allele. Neurology. 
2004;62(11):1990–1995. doi:10.1212/01.wnl.0000129533.26544.bf 
Caselli RJ, Reiman EM, Locke DE, et al. (2007). Cognitive domain decline in healthy 
apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive 
impairment. Archives of Neurology. 2007; 64(9):1306–1311. 
doi:10.1001/archneur.64.9.1306 
Csukly, G., Sirály, E., Fodor, Z., Horváth, A., Salacz, P., Hidasi, Z., Csibri, É., Rudas, G., 
& Szabó, Á. (2016). The Differentiation of Amnestic Type MCI from the Non-
Amnestic Types by Structural MRI. Frontiers in Aging Neuroscience, 8,  52. 
https://doi.org/10.3389/fnagi.2016.00052 
29 
Davatzikos, C., Bhatt, P., Shaw, L. M., Batmanghelich, K. N., & Trojanowski, J. Q. 
(2011). Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern 
classification. Neurobiology of Aging, 32(12), 2322.e19–2322.e2.322E27. 
https://doi.org/10.1016/j.neurobiolaging.2010.05.023 
De Flores, R., La Joie R., Chételat, G. (2015). Structural Imaging of Hippocampal 
Subfields in Healthy Aging and Alzheimer’s Disease. Neuroscience 309: 29–50. 
Delhaye, E., Mechanic-Hamilton, D., Saad, L., Das, S. R., Wisse, L., Yushkevich, P. A., 
Wolk, D. A., & Bastin, C. (2019). Associative memory for conceptually unitized word 
pairs in mild cognitive impairment is related to the volume of the perirhinal 
cortex. Hippocampus, 29(7), 630–638. https://doi.org/10.1002/hipo.23063 
Desikan, R., Ségonne, F., Fischl, B. et al. (2006). An Automated Labeling System for 
Subdividing the Human Cerebral Cortex on MRI Scans into Gyral Based Regions of 
Interest. NeuroImage 31, no. 3: 968–80. 
Devivo, R., Zajac, L., Mian, A., Cervantes-Arslanian, A., Steinberg, E., Alosco, M. L., … 
Killany, R. (2019). Differentiating Between Healthy Control Participants and Those 
with Mild Cognitive Impairment Using Volumetric MRI Data. Journal of the 
International Neuropsychological Society, 25(08), 800–810. doi: 
10.1017/s135561771900047x 
Galetta, K. M., Chapman, K. R., Essis, M. D., Alosco, M. L., Gillard, D., Steinberg, E., 
Dixon, D., Martin, B., Chaisson, C. E., Kowall, N. W., Tripodis, Y., Balcer, L. J., & 
Stern, R. A. (2017). Screening Utility of the King-Devick Test in Mild Cognitive 
Impairment and Alzheimer Disease Dementia. Alzheimer Disease and Associated 
Disorders, 31(2), 152–158. https://doi.org/10.1097/WAD.0000000000000157 
Gallagher, M., & Chiba, A. A. (1996). The amygdala and emotion. Current Opinion in 
Neurobiology, 6(2), 221–227. doi: 10.1016/s0959-4388(96)80076-6 
Gauthier S, Reisberg B, Zaudig M, et al. Mild cognitive impairment. Lancet. 
2006;367(9518):1262–1270. doi:10.1016/S0140-6736(06)68542-5 
Hebert, L. E., Beckett, L. A., Scherr, P. A., & Evans, D. A. (2001). Annual Incidence of 
Alzheimer Disease in the United States Projected to the Years 2000 Through 
2050. Alzheimer Disease and Associated Disorders, 15(4), 169–173. doi: 
10.1097/00002093-200110000-00002 
30 
Hobel, Z., Isenberg, A. L., Raghupathy, D., Mack, W., Pa, J., & Alzheimer’s Disease 
Neuroimaging Initiative and the Australian Imaging Biomarkers and Lifestyle flagship 
study of ageing (2019). APOEɛ4 Gene Dose and Sex Effects on Alzheimer's Disease 
MRI Biomarkers in Older Adults with Mild Cognitive Impairment. Journal of 
Alzheimer's disease: JAD, 71(2), 647–658. https://doi.org/10.3233/JAD-180859 
Iglesias, J. E., Augustinack, J. C., Nguyen, K., Player, C. M., Player, A., Wright, M., 
Leemput, K. V. at al. (2015). A computational atlas of the hippocampal formation using 
ex vivo , ultra-high resolution MRI: Application to adaptive segmentation of in vivo 
MRI. NeuroImage, 115, 117–137. doi: 10.1016/j.neuroimage.2015.04.042 
Iglesias J. E., Van Leemput K, Augustinack J, Insausti R, Fischl B, Reuter M. (2016). 
Bayesian longitudinal segmentation of hippocampal substructures in brain MRI using 
subject-specific atlases. Neuroimage, 141, November 2016, 542-555. 
Jack, C., Bernstein, M., Fox, N., et al. (2008). The Alzheimer’s Disease Neuroimaging 
Initiative (ADNI): MRI Methods. Journal of Magnetic Resonance Imaging 27, no. 4: 
685–691. https://doi.org/10.1002/jmri.21049 
Liu Y, Yu JT, Wang HF, et al. APOE genotype and neuroimaging markers of Alzheimer's 
disease: systematic review and meta-analysis. Journal of Neurology, Neurosurgery, 
and Psychiatry. 2015; 86(2):127–134. doi:10.1136/jnnp-2014-307719 
Lupton, M. K., Strike, L., Hansell, N. K., Wen, W., Mather, K. A., Armstrong, N. J., 
Thalamuthu, A., McMahon, K. L., de Zubicaray, G. I., Assareh, A. A., Simmons, A., 
Proitsi, P., Powell, J. F., Montgomery, G. W., Hibar, D. P., Westman, E., Tsolaki, M., 
Kloszewska, I., Soininen, H., Mecocci, P., … Wright, M. J. (2016). The effect of 
increased genetic risk for Alzheimer's disease on hippocampal and amygdala 
volume. Neurobiology of Aging, 40, 68–77. 
https://doi.org/10.1016/j.neurobiolaging.2015.12.023 
McDonald, A. J., & Mott, D. D. (2017). Functional neuroanatomy of 
amygdalohippocampal interconnections and their role in learning and memory. Journal 
of Neuroscience Research,  95(3), 797–820. https://doi.org/10.1002/jnr.23709 
Morris, J. (1993). The Clinical Dementia Rating (CDR): Current version and scoring rules. 
Neurology. 43: 2412–2414. 
Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C., Jagust, W., 
Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2005). The Alzheimer's disease 
neuroimaging initiative. Neuroimaging Clinics of North America, 15(4), 869–xii. 
https://doi.org/10.1016/j.nic.2005.09.008 
31 
National Institute on Aging (2020). What Are the Signs of Alzheimer’s Disease? Retrieved 
from https://www.nia.nih.gov/health/what-are-signs-alzheimers-disease 
Nickl-Jockschat, T., Kleiman, A., Schulz, J. B., Schneider, F., Laird, A. R., Fox, P. T., 
Eickhoff, S. B., & Reetz, K. (2012). Neuroanatomic changes and their association with 
cognitive decline in mild cognitive impairment: a meta-analysis. Brain structure & 
function, 217(1), 115–125. https://doi.org/10.1007/s00429-011-0333-x 
Petersen, R. C. (1995). Apolipoprotein E status as a predictor of the development of 
Alzheimers disease in memory-impaired individuals. JAMA: The Journal of the 
American Medical Association,  273(16), 1274–1278. doi: 10.1001/jama.273.16.1274 
Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., … Winblad, 
B. (2001). Current Concepts in Mild Cognitive Impairment. Archives of
Neurology, 58(12). doi: 10.1001/archneur.58.12.1985
Saygin, Z., Kliemann, D., Iglesias, J., Kouwe, A. V. D., Boyd, E., Reuter, M., Augustinack, 
J. et al. (2017). High-resolution magnetic resonance imaging reveals nuclei of the
human amygdala: manual segmentation to automatic atlas. NeuroImage, 155, 370–
382. doi: 10.1016/j.neuroimage.2017.04.046
Scoville, W. B., & Milner, B. (1957). Loss Of Recent Memory After Bilateral 
Hippocampal Lesions. Journal of Neurology, Neurosurgery & Psychiatry, 20(1), 11–
21. doi: 10.1136/jnnp.20.1.11
Squire L. R., Stark C. E., Clark R. E. (2004). The medial temporal lobe. Annual Review of 
Neuroscience. 27, 279–306. 
Tang, X., Holland, D., Dale, A. M., Miller, M. I., & Alzheimer's Disease Neuroimaging 
Initiative (2015). APOE Affects the Volume and Shape of the Amygdala and the 
Hippocampus in Mild Cognitive Impairment and Alzheimer's Disease: Age 
Matters. Journal of Alzheimer's disease: JAD, 47(3), 645–660. 
https://doi.org/10.3233/JAD-150262 
Tsao, A., Sugar, J., Lu, L. et al. Integrating time from experience in the lateral entorhinal 
cortex. Nature 561, 57–62 (2018). https://doi.org/10.1038/s41586-018-0459-6 
V. Di Marino et al. (2016) The Amygdaloid Nuclear Complex: Anatomic Study of the




Zanchi, D., Giannakopoulos, P., Borgwardt, S., Rodriguez, C., & Haller, S. (2017). 
Hippocampal and Amygdala Gray Matter Loss in Elderly Controls with Subtle 
Cognitive Decline.  Frontiers in aging neuroscience,  9, 50. 
https://doi.org/10.3389/fnagi.2017.00050 
 
Zidan M, Boban J, Bjelan M, et al. (2019). Thalamic volume loss as an early sign of 
amnestic cognitive impairment. Journal of Clinical Neuroscience. 2019 68:168-173. 
doi: 10.1016/j.jocn.2019.07.004. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
33 
CURRICULUM VITAE 
 
34 
 
